Areas of Interest & Competitive Research Grants - Bristol Myers Squibb

Areas of Interest (AOI)

Bristol Myers Squibb seeks Independent Research applications across all therapeutic areas.  Our Areas of Interest outline additional criteria to help guide the scientific community.  All concept applications submitted that best align with our interests will be considered and evaluated. Concepts may be submitted outside of the posted AOIs, but the threshold for approval may be relatively high.

The criteria will include, but not be limited to:

  • Specific therapeutic area of interest
  • The type of science we are seeking
  • We may include a specific window of time for all concept applications to be submitted
Therapeutic Area and / or Asset AOIs Posted on BMS.com Pre-Concept Submission Period
Start Date End date
Hematology 23-Nov-20 18-Jan-21 5-Feb-21
Immunology – ZEPOSIA® (ozanimod) Multiple Sclerosis 23-Nov-20 4-Jan-21 22-Jan-21
Immunology – ZEPOSIA® (ozanimod) Ulcerative colitis 2-Dec-20 4-Jan-21 29-Jan-21
Immunology - ORENCIA® (abatacept) 9-Dec-20 18-Jan-21 5-Feb-21
Oncology Jan 2021 29-Mar-21 23-Apr-21

 


Multiple Sclerosis – Zeposia (ozanimod) ISR Areas of Interest – 2021 RFP Cycle 1

 

In scope:

  • Ozanimod efficacy and safety in early RMS disease and/or diverse patient populations
  • RMS disease outcomes to include novel endpoints such as cognition, neuroimaging, biomarkers and/or patient reported outcomes
  • Exploring the impact of ozanimod on immune function (in vitro/in vivo)
  • Direct effect of ozanimod in the central nervous system using advanced imaging or human cell-based models

Out of scope:

  • Pediatric studies
  • Indications outside of multiple sclerosis
  • Combination with other disease modifying therapies
  • Alternative dosing other than 0.92 mg QD

Hematology Assets

 

Myeloid - CC-486 (azacitidine tablets) ISR Areas of Interest – 2021 RFP Cycle 1

 

In scope:

  • Efficacy and safety of CC-486 in HR MDS
  • Evaluation of CC-486 combinations in various AML subpopulations

Myeloid - Luspatercept ISR Areas of Interest - 2021 RFP Cycle 1

 

In scope:

  • Evaluation of epidemiology, disease burden, and treatment patterns by country and region for B-thal
  • Luspatercept alone and in combination with other therapies in MDS and B-thal 
  • Effect of luspatercept on comorbidities and other physiological functions related to iron overload
  • Hematologic improvements of luspatercept on cell lineages beyond erythroid
  • Patient reported outcomes and at-home monitoring
  • Luspatercept use in other anemias other than MDS and B-thal
  • Luspatercept in conjunction with other treatments/therapies

Out of scope:

  • ESA treatment rescue post luspatercept failure
  • Luspatercept 1L monotherapy in del5q MDS pts

Myeloid - Fedratinib ISR Areas of Interest - 2021 RFP Cycle 1

 

In scope:

  • Use of fedratinib in other disease areas outside MF
  • Efficacy and safety of fedratinib alone and in combination for MF, including subpopulations of patients with high unmet need

Out of scope:

  • Fedratinib use as monotherapy in AML and essential thrombocythemia

Multiple Myeloma - Iberdomide ISR Areas of Interest - 2021 RFP Cycle 1

 

In scope:

  • Efficacy and safety of Iberdomide-based therapies in RRMM at first or second relapse
  • Efficacy and safety of Iberdomide-based therapies in combination with and following BCMA-targeted therapies
  • Efficacy and safety of Iberdomide-based therapies in NDMM, in both the transplant-eligible and –ineligible settings
  • Impact of Iberdomide on patient reported outcomes and QOL assessments

Out of scope:

  • Combination with melphalan

Multiple Myeloma - Elotuzumab ISR Areas of Interest - 2021 RFP Cycle 1

 

In scope:

  • Role of elotuzumab in combination with CELMoD compounds in patients with RRMM
  • Evaluate elotuzumab in combination with CELMoD compounds following BCMA-targeted therapies

Lymphoma - Nivolumab ISR Areas of Interest - 2021 RFP Cycle 1

 

In scope:

  • Novel combinations with nivolumab to augment efficacy in cHL patients with best response of SD or PR
  • Novel combinations with nivolumab in r/r cHL to address unmet needs

  • If you are a potential investigator who is interested in seeking support to conduct independent research involving  Nivolumab  in Japan, Taiwan, or Korea, click here
  • If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
  • If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
  • If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here
  • If you are a potential investigator who is interested in seeking support for independent research involving NKTR-214 (Bempegaldesleukin) & Nivolumab, click here
  • If you are a potential investigator who is interested in seeking support for independent research involving idecabtagene vicleucel or lisocabtagene maraleucel, click here

Competitive Research Grants

The Bristol Myers Squibb Competitive Research Grant process includes the submission of a concept application that meets the required criteria posted. Competitive Research Grants we post will include specific criteria that must be met for your application to be considered.

At this time, there are no competitive research grants available.

Click here for trademark information on Bristol Myers Squibb products.

 

Please click on the product name to see the Full U.S. Prescribing Information for ELIQUIS®, EMPLICITI, NULOJIX®, OPDIVO®, ORENCIA®, SPRYCEL®, YERVOY®, including Boxed WARNINGS for ELIQUIS®, NULOJIX®, and Boxed WARNING for YERVOY® regarding immune-mediated adverse reactions.


Begin a New Application
If interested in a product or an investigational compound not listed